Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men - short version
| Autor: | Alexander Nast, A. Finner, Anja Blumeyer, Pascal Reygagne, Myrto Trakatelli, V. Del Marmol, Ulrike Blume-Peytavi, Varvara Kanti, Antonella Tosti, Bianca Maria Piraccini, Andrew G. Messenger, G. Dobos |
|---|---|
| Přispěvatelé: | Kanti, V, Messenger, A, Dobos, G, Reygagne, P, Finner, A, Blumeyer, A, Trakatelli, M, Tosti, A, Del Marmol, V, Piraccini, Bm, Nast, A, Blume-Peytavi, U. |
| Rok vydání: | 2017 |
| Předmět: |
Male
medicine.medical_specialty Evidence-based practice Vasodilator Agents Dermatology 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Pharmacotherapy 5-alpha Reductase Inhibitors Quality of life Outcome Assessment Health Care Medicine Humans Low-Level Light Therapy Androgenetic alopecia therapy finasteride minoxidil Laser guidelines baldness skin and connective tissue diseases Hair transplantation Evidence-Based Medicine integumentary system business.industry Platelet-Rich Plasma Finasteride Alopecia Guideline Evidence-based medicine Dutasteride medicine.disease Infectious Diseases Hair loss Minoxidil 030220 oncology & carcinogenesis Practice Guidelines as Topic Drug Therapy Combination Female business medicine.drug Hair |
| Zdroj: | Journal of the European Academy of Dermatology and Venereology : JEADV. 32(1) |
| ISSN: | 1468-3083 |
| Popis: | Androgenetic alopecia is the most common hair loss disorder, affecting both men and women. Initial signs of androgenetic alopecia usually develop during teenage years leading to progressive hair loss with a pattern distribution. Moreover, its frequency increases with age and affects up to 80% Caucasian men and 42% of women. Patients afflicted with androgenetic alopecia may undergo significant impairment of quality of life. The European Dermatology Forum (EDF) initiated a project to develop evidence-based guidelines for the treatment of androgenetic alopecia. Based on a systematic literature research the efficacy of the currently available therapeutic options was assessed and therapeutic recommendations were passed in a consensus conference. The purpose of the guideline is to provide dermatologists with an evidence-based tool for choosing an efficacious and safe therapy for patients with androgenetic alopecia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text